Stocktoria
Bioventus Inc. BVS
Bioventus Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M | $321.2M |
| Gross profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M | $233.5M |
| R&D expense | $12.1M | $14.0M | $13.4M | $23.9M | $19.0M | $11.2M |
| SG&A expense | $314.0M | $343.8M | $303.9M | $332.1M | $254.3M | $193.1M |
| Operating income | $54.0M | -$15.2M | -$81.7M | -$167.2M | $12.1M | $21.2M |
| Income tax | -$1.6M | -$5.3M | $85,000 | -$44.4M | -$2.0M | $1.2M |
| Net income | $22.7M | -$36.1M | -$156.2M | -$158.7M | $19.4M | $16.4M |
| EPS (diluted) | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 | — |
| Operating cash flow | $74.7M | $38.8M | $17.5M | -$13.5M | $23.0M | $72.2M |
| Free cash flow | $72.1M | $37.8M | $10.2M | -$15.0M | $9.5M | $55.6M |
| Cash & equivalents | $51.2M | $41.6M | $37.0M | $30.2M | $43.9M | $86.8M |
| Inventory | $82.2M | $92.5M | $91.3M | $84.8M | $61.7M | $29.1M |
| Total assets | $683.6M | $728.0M | $810.9M | $1.4B | $1.2B | $494.5M |
| Total liabilities | $455.1M | $542.4M | $589.8M | $960.4M | $618.2M | $350.3M |
| Shareholders' equity | $228.4M | $185.6M | $221.1M | $412.2M | $607.7M | — |
Growth · year-over-year · Revenue CAGR 12.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -0.9% | +11.9% | +0.0% | +18.8% | +34.2% | — |
| Net income growth | — | — | — | -919.1% | +18.1% | — |
| Free cash flow growth | +90.8% | +272.3% | — | -258.5% | -83.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.